Stock Taper 
RADX
$2.41
▲ UP 6.64% (0.15)
KEY STATISTICS
Market Cap$3.10 M
52w High$16.25
52w Low$2.04
Dividend Yield—
Frequency—
P/E-0.41
Volume333.27K
Shares Out.1.29M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Riccardo Canevari
ABOUT
SECTOR
Healthcare
WENT PUBLIC
December 5, 2024
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
14
PRICE TARGET
Target High$6.00
Target Low$6.00
Target Median$6.00
Target Consensus$6.00
UPCOMING EARNINGS
DateFeb 26, 2027
DayFriday
Rev. Est.$699.25K
FEB
26
FRI
PRICE
$2.41 ▲ UP 6.64% (+$0.15)About Radiopharm Theranostics Limited
https://www.radiopharmtheranostics.com ↗Radiopharm Theranostics Limited develops radiopharmaceuticals for cancer diagnosis and therapy, including treatments for NSCLC, breast cancer, pancreatic, prostate, and brain metastases, with strategic partnerships to advance clinical development.
INDUSTRY
Biotechnology
A PRODUCT RADIOPHARM THERANOSTICS LIMITED IS KNOWN FOR
RAD 101
Radiopharm Theranostics' leading investigational diagnostic imaging agent, in Phase 2b trials, is designed to detect brain metastases with promising results.
Revenue by Geography
| Map | REGION | FY2024 |
|---|---|---|
 | UNITED STATES | $3.63M |
RATINGS SNAPSHOT
Overall rating: C
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book5
Overall Score2
INSIDER TRADES
★
DIRECTOR
HOPPER PAUL
— · 27.5M shares
2024-09-13
★
DIRECTOR
HOPPER PAUL
— · 1.4M shares
2025-07-01
★
DIRECTOR
HOPPER PAUL
— · 3.6M shares
2022-11-25
★
OFFICER: CHIEF MEDICAL OFFICER
Voliotis Dimitris
— · 7.7M shares
2028-07-01
MOST RECENT ANALYST GRADES
GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 KTTA | $0.56 | COMPARE |
 CYCN | $3.79 | COMPARE |
 BCLI | $1.12 | COMPARE |
 QNRX | $6.12 | COMPARE |
 CDIO | $1.85 | COMPARE |
 ADXN | $3.84 | COMPARE |
 TCRT | $1.60 | COMPARE |